Blog powered by Typepad

Your email address:

Powered by FeedBlitz

« Caveat Emptor (Buyer Beware) | Main | The Sweetness Tax »

December 17, 2007



An FDA advisory panel just recommended that the warning for Covidien’s Optimark and GE’s Omnisca—drugs in the family of medications known as gadolinium-based contrast agents (DBCAs)—be updated to restrict their use in patients with severe kidney disease because of the potential for an increased risk of nephrogenic systemic fibrosis (NSF). NSF causes thickening of the skin and organs. GBCAs carry a strong “black box” warning. This site has good information on this issue: http://www.gadolinium-mri.com/index.html

liposculpture guide

Kidney weakness shows in loss of condition and appetite, loss of interest and a certain dullness, possible intermittent vomitting, and/or thirstiness.

The comments to this entry are closed.

Vote for Josh's blog